$CEAD
CEA Industries Inc. Stock $cead

$cead Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224019229 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$1.761M	$234.5K	$4.683M
YoY Change	65.52%	-94.99%	168.43%
Cost Of Revenue	$1.581M	$388.9K	$3.829M
YoY Change	60.49%	-89.84%	131.53%
Gross Profit	$179.8K	-$154.4K	$853.3K
YoY Change	128.48%	-118.09%	842.74%
Gross Profit Margin	10.21%	-65.83%	18.22%
Selling, General & Admin	$653.2K	$760.1K	$1.021M
YoY Change	-12.93%	-25.53%	-34.69%
% of Gross Profit	363.26%		119.62%
Research & Development			$76.41K
YoY Change			-44.99%
% of Gross Profit			8.96%
Depreciation & Amortization	$4.710K	$6.914K	$7.500K
YoY Change	-37.12%	-7.81%	-12.38%
% of Gross Profit	2.62%		0.88%
Operating Expenses	$657.0K	$769.4K	$1.299M
YoY Change	-16.13%	-40.79%	-23.64%
Operating Profit	-$477.2K	-$923.8K	-$446.2K
YoY Change	-32.28%	107.06%	-72.31%
Interest Expense	$6.910K	$7.210K	$9.020K
YoY Change	-23.05%	-20.07%	176.69%
% of Operating Profit
Other Income/Expense, Net	$6.906K	$7.206K	$14.72K
YoY Change	-37.52%	-51.06%	-92.04%
Pretax Income	-$470.3K	-$916.6K	-$431.4K
YoY Change	-32.19%	112.45%	-69.68%
Income Tax
% Of Pretax Income
Net Earnings	-$470.3K	-$916.6K	-$431.4K
YoY Change	-32.19%	112.45%	-69.68%
Net Earnings / Revenue	-26.71%	-390.87%	-9.21%
Basic Earnings Per Share	-$0.66	-$0.11	-$0.05
Diluted Earnings Per Share	-$0.66	-$0.11	-$0.05
COMMON SHARES
Basic Shares Outstanding	8.213M shares	8.213M shares	8.076M shares
Diluted Shares Outstanding	711.5K shares	8.210M shares	8.072M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.33M	$11.60M	$15.95M
YoY Change	-20.23%	-27.27%	-27.62%
Cash & Equivalents	$11.33M	$11.60M	$15.95M
Short-Term Investments
Other Short-Term Assets	$614.7K	$227.5K	$471.1K
YoY Change	18.16%	-51.71%	-73.45%
Inventory	$23.67K	$245.9K	$441.1K
Prepaid Expenses
Receivables	$32.16K	$20.13K	$61.77K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$12.22M	$12.32M	$16.92M
YoY Change	-20.69%	-27.21%	-32.46%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.31K	$19.02K	$60.71K
YoY Change	-73.11%	-68.67%	-90.17%
Goodwill
YoY Change
Intangibles	$1.830K	$1.830K
YoY Change
Long-Term Investments
YoY Change
Other Assets	$14.75K	$14.75K	$14.75K
YoY Change	0.0%	0.0%	0.0%
Total Long-Term Assets	$332.1K	$364.4K	$513.8K
YoY Change	-30.78%	-29.09%	-59.39%
TOTAL ASSETS
Total Short-Term Assets	$12.22M	$12.32M	$16.92M
Total Long-Term Assets	$332.1K	$364.4K	$513.8K
Total Assets	$12.55M	$12.68M	$17.44M
YoY Change	-21.0%	-27.27%	-33.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$598.7K	$101.6K	$714.6K
YoY Change	113.26%	-85.78%	-1.98%
Accrued Expenses	$418.6K	$389.1K	$569.8K
YoY Change	-34.6%	-31.71%	-33.41%
Deferred Revenue	$393.4K	$540.0K	$1.103M
YoY Change	-37.15%	-51.03%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.411M	$1.031M	$2.387M
YoY Change	-8.8%	-56.82%	-66.41%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$198.0K	$228.9K	$348.2K
YoY Change	-38.0%	-34.25%	-24.22%
Total Long-Term Liabilities	$197.9K	$228.9K	$348.2K
YoY Change	-38.0%	-34.25%	-24.22%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.411M	$1.031M	$2.387M
Total Long-Term Liabilities	$197.9K	$228.9K	$348.2K
Total Liabilities	$1.609M	$1.260M	$2.735M
YoY Change	-13.79%	-53.95%	-63.85%
SHAREHOLDERS EQUITY
Retained Earnings	-$38.58M	-$38.11M	-$34.71M
YoY Change	8.96%	9.79%
Common Stock	$8.00	$82.00	$81.00
YoY Change	-90.12%	1.23%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.94M	$11.42M	$14.70M
YoY Change
Total Liabilities & Shareholders Equity	$12.55M	$12.68M	$17.44M
YoY Change	-21.0%	-27.27%	-33.76%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$470.3K	-$916.6K	-$431.4K
YoY Change	-32.19%	112.45%	-69.68%
Depreciation, Depletion And Amortization	$4.710K	$6.914K	$7.500K
YoY Change	-37.12%	-7.81%	-12.38%
Cash From Operating Activities	-$273.4K	-$909.4K	-$2.689M
YoY Change	-84.38%	-66.18%	-1494.4%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$200.00
YoY Change		-100.0%
Cash From Investing Activities	$0.00		$200.00
YoY Change			-101.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities	-273.4K	-$909.4K	-$2.689M
Cash From Investing Activities	0.000		$200.00
Cash From Financing Activities
Net Change In Cash	-273.4K	-$909.4K	-$2.689M
YoY Change	-84.38%	-66.18%	-113.53%
FREE CASH FLOW
Cash From Operating Activities	-$273.4K	-$909.4K	-$2.689M
Capital Expenditures
Free Cash Flow			-$2.689M
YoY Change			-1400.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2024Q1	CEAD	Options Issued For Accrued Equity Compensation Liability OptionsIssuedForAccruedEquityCompensationLiability		usd
CY2023Q4	CEAD	Class Of Warrant Or Right Outstanding Aggregate Intrinsic Value ClassOfWarrantOrRightOutstandingAggregateIntrinsicValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted		shares
CY2024Q1	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableGranted		shares
CY2024Q1	CEAD	Class Of Warrant Or Right Weighted Average Exercise Price Granted ClassOfWarrantOrRightWeightedAverageExercisePriceGranted
CY2024Q1	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Granted Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsGrantedWeightedAverageRemainingContractualTerms
CY2024Q1	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Granted SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueGranted		usd
CY2024Q1	CEAD	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised		shares
CY2024Q1	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExercised		shares
CY2024Q1	CEAD	Class Of Warrant Or Right Weighted Average Exercise Price Exercised ClassOfWarrantOrRightWeightedAverageExercisePriceExercised
CY2024Q1	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Exercised Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExercisedWeightedAverageRemainingContractualTerms
CY2024Q1	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Exercised SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExercised		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations		shares
CY2024Q1	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableExpirations		shares
CY2024Q1	CEAD	Class Of Warrant Or Right Weighted Average Exercise Price Expired ClassOfWarrantOrRightWeightedAverageExercisePriceExpired
CY2024Q1	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Expired Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsExpiredWeightedAverageRemainingContractualTerms
CY2024Q1	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Expirations SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueExpirations		usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-41266
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	CEA INDUSTRIES INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	27-3911608
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	385 South Pierce Avenue
CY2024Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite C
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Louisville
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CO
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80027
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	80027
CY2024Q1	dei	City Area Code CityAreaCode	(303)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	993-5271
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8212737	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11598836	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12508251	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	20126	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18655	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	245894	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	296404	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	227514	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	313115	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	12316784	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	13360839	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19019	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38558	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1830	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1830	usd
CY2024Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	14747	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	14747	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	328792	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	356109	usd
CY2024Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	364388	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	411244	usd
CY2024Q1	us-gaap	Assets Assets	12681172	usd
CY2023Q4	us-gaap	Assets Assets	13772083	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	361876	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	624724	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	539956	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	499800	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	128839	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	126724	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1030671	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1251248	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	228927	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	259627	usd
CY2024Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	228927	usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	259627	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1259598	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1510875	usd
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8212737	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8212737	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8076372	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8076372	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	82	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	81	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49528387	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49451419	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38106895	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-37190292	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	11421574	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12261208	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12681172	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13772083	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	-154375	usd
CY2024Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	9324	usd
CY2023Q1	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	202323	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	76413	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	760110	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1020702	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	769434	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	1299438	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-923809	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-446162	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5704	usd
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	7206	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	9020	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7206	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14724	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-916603	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-431438	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-916603	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-431438	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8209730	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8209730	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8071731	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8071731	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12261208	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1969	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	75000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-916603	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	11421574	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14895175	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14895175	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	135748	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Restricted Stock Units Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition	101316	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-431438	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	14700801	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	14700801	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-916603	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-431438	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6914	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	7500	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	76969	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	147094	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-34566	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-1705	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	38360	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	33638	usd
CY2024Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-12625	usd
CY2023Q1	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-100	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	27317	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	26325	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-33096	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	57420	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-12151	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	126360	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-85600	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1018785	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-262849	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-43124	usd
CY2024Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	40156	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-3235970	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-28585	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-26662	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-909415	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2689237	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	200	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	200	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-909415	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2689037	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12508251	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	18637114	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11598836	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	15948077	usd
CY2023Q1	CEAD	Options Issued For Accrued Equity Compensation Liability OptionsIssuedForAccruedEquityCompensationLiability	89970	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4682573	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	21711000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_843_eus-gaap--UseOfEstimates_zKo2SG375nFe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_zKObAja6ogph">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management makes estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and that affect the reported amounts of revenue and expenses during the reporting period. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. Key estimates include: allocation of transaction prices to performance obligations under contracts with customers, standalone selling prices, timing of expected revenue recognition on remaining performance obligations under contracts with customers, valuation of intangible assets as it applies to impairment analysis, valuation of equity-based compensation, valuation of deferred tax assets and liabilities, warranty accruals, inventory allowances, and legal contingencies.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11599000	usd
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	11349000	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	91000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	125000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-34566	usd
CY2024Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	7942220	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	8010956	shares
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	234506	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1436	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	1436	usd
CY2024Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	224414	usd
CY2024Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	539956	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	499800	usd
CY2024Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	47440	usd
CY2023Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3852906	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	535000	usd
CY2023Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	1869000	usd
CY2024Q1	CEAD	Remaining Performance Obligations Related To Partial Equipment Paid Contracts RemainingPerformanceObligationsRelatedToPartialEquipmentPaidContracts	535000	usd
CY2024Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	535000	usd
CY2024Q1	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The Company assesses the historical warranty claims on its manufactured products and, since 2016, warranty claims have been approximately 1% of annual revenue generated on these products. Based on the Company’s warranty policy, an accrual is established at 1% of the trailing 18 months revenue.
CY2024Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	99470	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	191338	usd
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	76969	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	147094	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	355138	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	366844	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	121814	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	122258	usd
CY2024Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	231058	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zB3hvBnAdNbh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_863_zuPQcADrLoa3">Concentrations</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three customers accounted for<span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zmKrzf4HhQT4" title="Concentration risk percentage"> 24</span>%, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zl9QLympP1Af" title="Concentration risk percentage">16</span>%, and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zgin678gufxl" title="Concentration risk percentage">13</span>% of the Company’s revenue, respectively, for the three months ended March 31, 2024. Three customers accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zMcBjIvXAFQa" title="Concentration risk percentage">39</span>%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zFia1EQssYih" title="Concentration risk percentage">28</span>%, and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zz7SFs4G4ZZd" title="Concentration risk percentage">17</span>% of the Company’s revenue, respectively, for the three months ended March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three customers accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zMQFRRtlIaQ" title="Concentration risk percentage">60</span>%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zuroVGILqQy4" title="Concentration risk percentage">29</span>%, and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zN9kEeQeI8U3" title="Concentration risk percentage">11</span>% of the Company’s accounts receivable, respectively, as of March 31, 2024. Three customers accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zkHUIPcSQTgc" title="Concentration risk percentage">59</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zU1LxG6LsKX5" title="Concentration risk percentage">29</span>%, and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zFqpckwyaEW" title="Concentration risk percentage">12</span>% of the Company’s accounts receivable, respectively, as of December 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	328792	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	128839	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	228927	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y9M18D
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0363	pure
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	32001	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	96643	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	132503	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	136473	usd
CY2024Q1	CEAD	Lessee Operating Lease Liability Payments Due After Year Two LesseeOperatingLeaseLiabilityPaymentsDueAfterYearTwo	11654	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	377273	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	19507	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	357766	usd
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	192698	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	245894	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	296404	usd
CY2024Q1	us-gaap	Cost Of Goods And Services Sold Overhead CostOfGoodsAndServicesSoldOverhead	11475	usd
CY2023	us-gaap	Cost Of Goods And Services Sold Overhead CostOfGoodsAndServicesSoldOverhead	13679	usd
CY2024Q1	CEAD	Prepaid Inventory Expenses PrepaidInventoryExpenses	13000	usd
CY2023Q4	CEAD	Prepaid Inventory Expenses PrepaidInventoryExpenses	6000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	264511	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	290994	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	245492	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	252436	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	19019	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38558	usd
CY2024Q1	us-gaap	Depreciation Depreciation	6914	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	101591	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	183359	usd
CY2024Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1706	usd
CY2023Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1710	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	143165	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	189829	usd
CY2024Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	99470	usd
CY2023Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	191338	usd
CY2024Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	15944	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	58488	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	361876	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	624724	usd
CY2023Q4	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	1049280	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	8212737	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	8212737	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7623772	shares
CY2023Q4	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	7623772	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.14
CY2024Q1	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Terms SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerms	P37M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7623772	shares
CY2024Q1	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	7623772	shares
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.14
CY2024Q1	CEAD	Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm	P34M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	7623772	shares
CY2024Q1	CEAD	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	7623772	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P34M
CY2024Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	29757000	usd
CY2024Q1	CEAD	Net Operating Loss Carry Forward Expected To Expire Amount NetOperatingLossCarryForwardExpectedToExpireAmount	11196000	usd
CY2024Q1	CEAD	Net Operating Loss Expiration Term NetOperatingLossExpirationTerm	2034 through 2037
CY2024Q1	CEAD	Nols Usage Against Taxable Income Percentage NolsUsageAgainstTaxableIncomePercentage	0.80	pure
CY2024Q1	CEAD	Nols Carryforwards Term Description NolsCarryforwardsTermDescription	three-year period
CY2024Q1	us-gaap	Payments For Commissions PaymentsForCommissions	0	usd
CY2023Q1	us-gaap	Payments For Commissions PaymentsForCommissions	18273	usd
CY2023Q1	us-gaap	Payments For Deposits PaymentsForDeposits	14035	usd
CY2024Q1	us-gaap	Subsequent Event Description SubsequentEventDescription	April 10, 2023 the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that, based upon the closing bid price of the Company’s common stock for the 30 consecutive business day period between February 24, 2023, through April 6, 2023, the Company did not meet the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2).

Files In Submission

Name	View Source	Status
0001493152-24-019229-index-headers.html	Edgar Link	pending
0001493152-24-019229-index.html	Edgar Link	pending
0001493152-24-019229.txt	Edgar Link	pending
0001493152-24-019229-xbrl.zip	Edgar Link	pending
cead-20240331.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
cead-20240331_def.xml	Edgar Link	unprocessable
cead-20240331_lab.xml	Edgar Link	unprocessable
cead-20240331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cead-20240331_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CEAD
CEA Industries Inc. Stock $cead

2024 Q2 Form 10-Q Financial Statement

#000149315224019229 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CEAD CEA Industries Inc. Stock $cead

2024 Q2 Form 10-Q Financial Statement

#000149315224019229 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CEAD
CEA Industries Inc. Stock $cead